S2276 Response of Autoimmune Gastroparesis to Immunomodulation

Madison Simons,Jack Loesch,Eyad Hamza,Anthony J. Lembo,Michael Cline,Matthew Allemang,Andrew D. Grubic
DOI: https://doi.org/10.14309/01.ajg.0001038472.07898.80
2024-10-26
The American Journal of Gastroenterology
Abstract:Gastroparesis is a chronic digestive condition in which a delay in gastric emptying is associated with symptoms including early satiety, excessive fullness, nausea, vomiting, and abdominal pain. Recent evidence suggests autoimmune factors may be involved in the development of gastroparesis, a subtype known as autoimmune gastrointestinal dysmotility (AGID). Additionally, small open label studies in gastroparetic patients with autoimmune markers have demonstrated intravenous immunoglobulin (IVIG) therapy leads to improvement in symptoms and gastric emptying. We aimed to evaluate the effects of IVIG therapy on symptom severity in patients with gastroparesis.
gastroenterology & hepatology
What problem does this paper attempt to address?